Gastrointestinal Cancer News

The FDA granted orphan drug designation to tarextumab for the treatment of pancreatic cancer and small cell lung cancer, the drug’s manufacturer announced today.

When combined with tissue sampling, using probe-based confocal laser endomicroscopy during endoscopic retrograde cholangio-pancreatography diagnosed cholangiocarcinoma with greater accuracy and sensitivity compared with standard procedures, according to new research data.

Lanreotide demonstrated antitumor activity with a manageable safety profile in patients with pancreatic neuroendocrine tumors, according to a subgroup analysis of the CLARINET study presented at the Gastrointestinal Cancers Symposium.

The incidence of colorectal cancer is increasing among the young adult population while decreasing among adults in the screened population, according to new research data.

The novel agent pembrolizumab demonstrated promising antitumor activity and manageable toxicity in patients with advanced gastric cancer, according to study results presented at the Gastrointestinal Cancers Symposium.

Providing fair, high-quality, evidence-based care can eliminate racial disparities in survival outcomes among patients with colon cancer, according to results of a retrospective study.

The addition of the novel agent MM-398 to second-line 5-FU/leucovorin extended survival in patients with metastatic pancreatic cancer, according to an expanded analysis of the phase 3 NAPOLI-1 trial presented at the Gastrointestinal Cancer Symposium.

Combination treatment with temsirolimus and bevacizumab demonstrated considerable activity and a reasonable safety profile in patients with progressive pancreatic neuroendocrine tumors, according to results of a phase 2 trial.

A somatic mutation in the ATP-dependent helicase, or ATRX,  gene — recently demonstrating potential as a molecular marker for aggressive brain tumors — could also serve as a biomarker for rare neuroendocrine tumors, according to research published in Nature Communications.

Different molecular subtypes of colorectal cancer were found to be associated with significant differences in patient survival, according to new research data.